The dual role of serotonin in defense and the mode of action of antidepressants on generalized anxiety and panic disorders

Central Nervous System Agents in Medicinal Chemistry

Volumn 10, Issue 3, 2010, Pages 207-217

  Graeff, Frederico Guilherme ^a   Hélio Jr , Zangrossi ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Animal models; Antidepressants; Anxiety disorders; Human experimental anxiety; Neuroimaging; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR;

ACUTE DRUG ADMINISTRATION; AMYGDALOID NUCLEUS; ARTICLE; CHRONIC DRUG ADMINISTRATION; DRUG ACTIVITY; DRUG MECHANISM; FOREBRAIN; GENERALIZED ANXIETY DISORDER; HUMAN; MESENCEPHALON; NEUROIMAGING; NONHUMAN; PANIC; PERIAQUEDUCTAL GRAY MATTER; PREFRONTAL CORTEX;

EID: 77956436494     PISSN: 18715249     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871524911006030207     Document Type: Article

References (90)

1. American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed; APA Press: Washington, DC, 1994.
2. Klein, F.F.; Flink, M. Psychiatric reaction patterns to imipramine. Am. J. Psychiatry, 1962, 11 9(1), 432-438.
3. Kahn, R.J.; McNair, D.M.; Lipman, R.S.; Covi, L.; Rickels, K.; Downing, R.; Fisher, S.; Frankenthaler, L.M. Imipramine and chlordiazepoxide in depressive and anxiety disorders. II-Efficacy in anxious outpatients. Arch. Gen. Psychiatry, 1986, 43(1), 79-85.
4. Baldwin, D.S.; Anderson, I.M.; Nutt, D.J.; Bandelow, B.; Bond, A.; Davidson, J.R.T.; den Boer, J.A.; Fineberg, N.A.; Knapp, M.; Scott, J.; Wittchen, H.-U. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol., 2005, 19(6), 567-596.
5. Blier, P.; Abbott, F.V. Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J. Psychiatry Neurosci., 2001, 26(1), 37-43.
6. Gordon, J.A.; Hen, R. The serotonergic system and anxiety. Neuromolecul. Med., 2004, 5(1), 27-40.
7. Guimarães, F.S.; Carobrez, A.P.; Graeff, F.G. In: Handbook of Anxiety and Fear; Blanchard, R.J.; Blanchard, D.C.; Griebel, G.; Nutt, D., Eds.; Elsevier Science B.V.: Amsterdan, 2008; pp. 241-268.
8. Millan, M.J. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie, 2006, 60(5), 441-460.
9. Bell, C.; Forshall, S.; Adrover, M.; Nash, J.; Hood, S.; Argyropoulos, S.; Rich, A.; Nutt, D.J. Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J. Psychopharmacol., 2002, 16(1), 5-14.
10. Argyropoulos, S.V.; Hood, S.D.; Adrover, M.; Bell, C.J.; Rich, A.S.; Nash, J.R.; Rich, N.C.; Witchel, H.J.; Nutt, D.J. Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biol. Psychiatry, 2004, 56(7), 503-509.
11. Maron, E.; Toru, I.; Vasar, V.; Shlik, J. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers. J. Psychopharmacol., 2004, 18(2), 194-199.
12. Schruers, K.; van Diest, R.; Overbeek, T.; Griez, E. Acute L-5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients. Psychiatry Res., 2002, 113(3), 237-243.
13. Miller, H.E.; Deakin, J.F.W.; Anderson, I.M. Effect of acute tryptophan depletion on CO2-induced anxiety in patients with panic disorder and normal volunteers. Br. J. Psychiatry, 2000, 176(1), 182-188.
14. Ben-Zion, I.Z.; Meiri, G.; Greenberg, B.D.; Murphy, D.L.; Benjamin, J. Enhancement of CO2-induced anxiety in healthy volunteers with the serotonin antagonist metergoline. Am. J. Psychiatry, 1999, 156(10), 1635-1637.
15. Corchs, F.; Nutt, D.J.; Hood, S.; Bernik, M. Serotonin and sensitivity to trauma-related exposure in selective serotonin reuptake inhibitors-recovered posttraumatic stress disorder. Biol. Psychiatry, 2009, 66(1), 17-24.
16. Barr, L.C.; Goodman, W.K.; McDougle, C.J.; Delgado, P.L.; Heninger, G.R.; Charney, D. S.; Price, L.H. Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch. Gen. Psychiatry, 1994, 51(4), 309-317.
17. Hood, S.D.; Hince, D.A.; Davies, S.J.; Argyropoulos, S.; Robinson, H.; Potokar, J.; Nutt, D.J. Effects of acute tryptophan depletion in serotonin reuptake inhibitor-remitted patients with generalized anxiety disorder. Psychopharmacology, 2010, 208(2), 223-232.
18. Santarelli, L.; Saxe, M.; Gross, C.; Surget, A.; Battaglia, F.; Dulawa, S.; Weisstaub, N.; Lee, J.; Duman, R.; Arancio, O.; Belzung, C.; Hen, R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science, 2003, 301(5634), 805-809.
19. Saarelainen, T.; Hendolin, P.; Lucas, G.; Koponen, E.; Sairanen, M.; MacDonald, E.; Agerman, K.; Haapasalo, A.; Nawa, H.; Aloyz, R.; Ernfors, P.; Castrén, E. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J. Neurosci., 2003, 23(1), 349-357.
20. Hoyer, D.; Hannon, J.P.; Martin, G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav., 2002, 71(4), 533-554.
21. Hensler, J.G. Serotonergic modulation of the limbic system. Neurosci. Biobehav. Rev., 2006, 30(2), 203-214.
22. Clark, M.S.; McDevitt, R.A.; Neumaier, J.F. Quantitative mapping of tryptophan hydroxilase-2, 5-HT1A, 5-HT1B, and serotonin transporter expression across the anteroposterior axis of the rat dorsal and median raphe nuclei. J. Comp. Neurol., 2006, 498(5), 611-623.
23. Lowry, C.A.; Johnson, P.L.; Hay-Schmidt, A.; Mikkelsen, J.; Shekhar, A. Modulation of anxiety circuits by serotonergic systems. Stress, 2005, 8(4), 233-246.
24. Griebel, G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol. Ther., 1995, 65(3), 319-395.
25. Millan, M.J. The neurobiology and control of anxious states. Prog. Neurobiol., 2003, 70(2), 83-244.
26. Hunsperger, R. W. Role of substantia grisea centralis mesencephali in electrically-induced rage reactions. Prog. Neurobiol., 1956, 2(1), 289-294.
27. Blanchard, D.C.; Blanchard, R.J. Ethoexperimental approaches to the biology of emotion. Annu. Rev. Psychol., 1988, 39(1), 43-68.
28. Fanselow, M.S. In: The Midbrain Periaqueductal Gray Matter: Functional, Anatomical and Immunohistochemical Organization; Depaulis, A.; Bandler, R., Eds.; Plenum Press: New York, 1991; pp. 151-173.
29. Delgado, J.M.R.; Roberts, W.W.; Miller, N.E. Learning motivated by electrical stimulation of the brain. Am. J. Physiol., 1954, 179(3), 587-593.
30. Graeff, F.G. On serotonin and experimental anxiety. Psychopharmacology, 2002, 163(3-4), 467-476.
31. Blanchard, D.C.; Hynd, A.L.; Minke, K.A.; Minemoto, T.; Blanchard, R.J. Human defensive behaviors to threat scenarios show parallels to fear-and anxiety-related defense patterns on non-human mammals. Neurosci. Biobehav. Rev., 2001, 25(7-8), 761-770.
32. Shuhama, R.; Del-Ben, C.M.; Loureiro, S.; Graeff, F.G. Animal defense strategies and anxiety disorders. An. Acad. Bras. Cienc., 2007, 79(1), 97-109.
33. Azmitia, E.C.; Segal, M. An autodiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J. Comp. Neurol., 1978, 179(3), 641-688.
34. Mamounas, L. A.; Mullen, C.A.; O'Hearn, E.; Molliver, M.E. Dual serotoninergic projections to forebrain in the rat: morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives. J. Comp. Neurol., 1991, 314(3), 558-586.
35. Graeff, F.G. In: New Concepts in Anxiety; Briley, M.; File, S.E., Eds.; Macmillan Press: London, 1991, pp. 288-312.
36. Deakin, J.F.W.; Graeff, F.G. 5-HT and mechanisms of defence. J. Psychopharmacol., 1991, 5(4), 305-315.
37. Graeff, F.G.; Viana, M.B.; Tomaz C. The elevated T maze, a new experimental model of anxiety and memory: effect of diazepam. Braz. J. Med. Biol. Res., 1993, 26(1), 67-70.
38. Viana, M.B.; Tomaz, C.; Graeff, F.G. The elevated T-maze: a new animal model of anxiety and memory. Pharmacol. Biochem. Behav., 1994, 49(3), 549-554.
39. Graeff, F.G.; Netto, C.F.; Zangrossi, H.Jr. The elevated T-maze as an experimental model of anxiety. Neurosci. Biobehav. Rev., 1998, 23(2), 237-246.
40. Graeff, F.G.; Zangrossi, H. Jr. In: Textbook of Biological Psychiatry; D'haenen, H.; Den Boer, J.A.; Westenberg, H.; Willner, P., Eds.; Wiley and Sons: London, 2002, pp. 879-893.
41. Pinheiro, S.H.; Zangrossi, H. Jr.; Del-Ben, C.M.; Graeff, F.G. Elevated mazes as animal models of anxiety: effects of serotonergic agents. An. Acad. Bras. Cienc., 2007, 79(1), 71-85.
42. Graeff, F.G.; Del-Ben, C.M. Neurobiology of panic disorder: from animal models to brain neuroimaging. Neurosci. Biobehav. Rev., 2008, 32(7), 1326-1335.
43. Nogueira, R.L.; Graeff, F.G. Role of 5-HT receptor subtypes in the modulation of dorsal periaqueductal gray generated aversion. Pharmacol. Biochem. Behav., 1995, 52(1), 1-6.
44. Zanoveli, J.M.; Nogueira, R.L.; Zangrossi, H.Jr. Serotonin in the dorsal periaqueductal gray modulates inhibitory avoidance and one-way escape behaviors in the elevated T-maze. Eur. J. Pharmacol., 2003, 473(2-3), 153-161.
45. De Paula Soares, V.; Zangrossi, H. Jr. Involvement of 5-HT1A and 5-HT2 receptors of the dorsal periaqueductal gray in the regulation of the defensive behaviors generated by the elevated T-maze. Brain. Res. Bull., 2004, 64(2), 181-188.
46. Mongeau, R.; Marsden, C.A. Effect of imipramine treatments on the 5-HT1A-receptor-mediated inhibition of panic-like behaviours in rats. Psychopharmacology, 1997, 131(40), 321-328.
47. Jacob, C.A.; Cabral, A.H.; Almeida, L.P.; Magierek, V. Chronic imipramine enhances 5-HT(1A) and 5-HT(2) receptors mediated inhibition of panic-like behavior in the rat dorsal periaqueductal gray. Pharmacol. Biochem. Behav., 2002, 72(4), 761-766.
48. De Bortoli, V.C.; Nogueira, R.L.; Zangrossi, H. Jr. Effects of fluoxetine and buspirone on the panicolytic-like response induced by the activation of 5-HT1A and 5-HT2A receptors in the rat dorsal periaqueductal gray. Psychopharmacology, 2006, 183(4), 422-428.
49. Zanoveli, J.M.; Nogueira, R.L.; Zangrossi, H. Jr. Chronic imipramine treatment sensitizes 5-HT1A and 5-HT2A receptors in the dorsal periaqueductal gray matter: evidence from the elevated Tmaze test of anxiety. Behav. Pharmacol., 2005, 16(7), 543-552.
50. Zanoveli, J.M.; Nogueira, R.L.; Zangrossi, H. Jr. Enhanced reactivity of 5-HT1A receptors in the rat dorsal periaqueductal gray matter after chronic treatment with fluoxetine and sertraline: evidence from the elevated T-maze. Neuropharmacology, 2007, 52(4), 1188-1195.
51. De Bortoli, V.C.; Nogueira, R.L.; Zangrossi, H. Jr. Alprazolam potentiates the antiaversive effect induced by the activation of 5-HT(1A) and 5-HT (2A) receptors in the rat dorsal periaqueductal gray. Psychopharmacology, 2008, 198(3), 341-349.
52. Zanoveli, J.M.; Pobbe, R.L.; de Bortoli, V.C.; Carvalho, M.C.; Brandão, M.L.; Zangrossi, H Jr. Facilitation of 5-HT1A-mediated neurotransmission in dorsal periaqueductal grey matter accounts for the panicolytic-like effect of chronic fluoxetine. Int. J. Neuropsychopharmacol. 2009, Nov 27:1-10. [Epub ahead of print].
53. Kreiss, D.S.; Lucki, I. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J. Pharmacol. Exper. Ther., 1995, 274(2), 866-876.
54. Dremencov, E.; Gur, E.; Lerer, B.; Newman, M.E. Effects of chronic antidepressants and electroconvulsive shock on serotonergic neurotransmission in the rat hippocampus. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003, 27(5), 729-739.
55. Johnson, D.A.; Grant, E.J.; Ingram, C.D.; Gartside, S.E. Glucocorticoid receptor antagonists hasten and augment neurochemical responses to a selective serotonin reuptake inhibitor antidepressant. Biol. Psychiatry, 2007, 62(11), 1228-1235.
56. Vertes, R.P. A PHA-L analysis of ascending projections of the dorsal raphe nucleus in the rat. J. Comp. Neurol., 1991, 313(4), 643-668.
57. Viana, M.B.; Graeff, F.G.; Löschmann PA. Kainate microinjection into the dorsal raphe nucleus induces 5-HT release in the amygdala and periaqueductal gray. Pharmacol. Biochem. Behav., 1997, 58(1), 167-172.
58. Poltronieri, S.C.; Zangrossi, H. Jr.; de Barros Viana, M. Antipaniclike effect of serotonin reuptake inhibitors in the elevated T-maze. Behav. Brain Res., 2003, 147(1-2), 185-192.
59. Pobbe, R.L.; Zangrossi, H. Jr. 5-HT(1A) and 5-HT(2A) receptors in the rat dorsal periaqueductal gray mediate the antipanic-like effect induced by the stimulation of serotonergic neurons in the dorsal raphe nucleus. Psychopharmacology, 2005, 183(3), 314-321.
60. Beck, S.G.; Birnstiel, S.; Choi, K.C.; Pouliot, W.A. Fluoxetine selectively alters 5-hydroxytryptamine1A and gamma-aminobutyric acid receptor-mediated hyperpolarization in area CA1, but not area CA3, hippocampal pyramidal cells. J. Pharmacol. Exp. Ther., 1997, 281(1), 115-122.
61. Millan, M.J. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie, 2005, 60(5), 441-460.
62. Dos Santos, L.; de Andrade, T.G.; Zangrossi, H. Jr. Serotonergic neurons in the median raphe nucleus regulate inhibitory avoidance but not escape behavior in the rat elevated T-maze test of anxiety. Psychopharmacology, 2005, 179(4), 733-741.
63. Viana, M. B.; Zangrossi, H. Jr.; Onusic, G.M. 5-HT1A receptors of the lateral septum regulate inhibitory avoidance but not escape behavior in rats. Pharmacol. Biochem. Behav., 2008, 89(3), 360-366.
64. McNaughton, N.; Corr, P.J. A two-dimensional neuropsychology of defense: fear/anxiety and defensive distance. Neurosci. Biobehav. Rev., 2004, 28(3) 285-305.
65. Mobbs, D.; Petrovic, P.; Marchant, J. L.; Hassabis, D.; Weiskopf, N.; Seymour, B.; Dolan, R. J.; Frith, C. D. When fear is near: threat imminence elicits prefrontal-periaqueductal gray shifts in humans. Science, 2007, 317(5841) 1079-1083.
66. Graeff, F.G.; Parente, A.; Del-Ben, C.M.; Guimarães, F.S. Pharmacology of human experimental anxiety. Braz. J. Med. Biol. Res., 2003, 36(4), 421-432.
67. Baldwin, D.S.; Polkinghorn, C. Evidence-based pharmacotherapy of Generalized Anxiety Disorder. Int. J. Neuropsychopharmacol., 2005, 8(2), 293-302.
68. Bakker, A.; van Balkom, A.J.; Stein, D.J. Evidence-based pharmacotherapy of panic disorder. Int. J. Neuropsychopharmacol., 2005, 8(3), 473-482.
69. Guimarães, F.S.; Zuardi, A.W.; Graeff, F.G. Effect of chlorimipramine and maprotiline on experimental anxiety in humans. J. Psychopharmacol., 1987, 1(1), 184-192.
70. Silva, M.; Hetem, L.A.; Guimarães, F.S.; Graeff, F.G. Opposed effects of nefazodone in two human models of anxiety. Psychopharmacology, 200, 1156(4), 454-460.
71. Bel, N.; Artigas, F. Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur. J. Pharmacol., 1992, 229(1), 101-103.
72. Del-Ben, C.M.; Vilela, J.A.A.; Hetem, L.A.B.; Guimarães, F.S.; Graeff, F.G.; Zuardi, A.W. Do panic patients process unconditioned fear versus conditioned anxiety differently from normal subjects? Psychiatry Res., 2001, 104(3), 227-237.
73. Garcia-Leal, C.; Parente, A.C.B.V.; Del-Ben, C.M.; Guimarães, F.S.; Moreira, A.C.; Elias, L.L.K.; Graeff, F.G. Anxiety and salivary cortisol in symptomatic and nonsymptomatic panic patients and healthy volunteers performing simulated public speaking. Psychiatry Res., 2005, 133(2-3), 239-252.
74. Parente, A.C.B.V.; Garcia-Leal, C.; Del-Ben, C.M.; Guimarães, F.S.; Graeff, F.G. Subjective and neurovegetative changes in healthy volunteers and panic patients performing simulated public speaking. Eur. Neuropsychopharmacol., 2005, 15(6), 663-671.
75. Graeff, F.G.; Zuardi, A.W.; Giglio, J.S.; Lima Filho, E.C.; Karniol, I.G. Effect of metergoline on human anxiety. Psychopharmacology, 1985, 86(3), 334-338.
76. Graeff, F.G.; Garcia-Leal, C.; Del-Ben, C.M.; Guimarães, F.S. Does the panic attack activate the hypothalamic-pituitary-adrenal axis? An. Acad. Brasil. Cienc., 2005, 77(3), 1-15.
77. Schenberg, L.C.; Dos Reis, A.M.; Ferreira Póvoa, R.M.; Tufik, S.; Silva, S.R. A panic attack-like unusual stress reaction. Horm. Behav., 2008, 54(5), 584-591.
78. Berkowitz, R.L.; Coplan, J.D.; Reddy, D.P.; Gorman, J.M. The human dimension: How the prefrontal cortex modulates the subcortical fear response. Rev. Neurosci., 2007, 18(3-4), 191-207.
79. Sakai, Y.; Kumano, H.; Nishikawa, M.; Sakano, Y.; Kaiya, H.; Imabayashi, E.; Ohnishi, T.; Matsuda, H.; Yasuda, A.; Sato, A.; Diksic, M.; Kuboki, T. Changes in cerebral glucose utilization in patients with panic disorder treated with cognitive-behavioral therapy. NeuroImage, 2006, 33(1), 218-226.
80. Hariri, A.R.; Drabant, E.M.; Munoz, K.E.; Kolachana, B.S.; Mattay, V.S.; Egan, M.F.; Weinberger, D.R. A susceptibility gene for affective disorders and the response of the human amygdala. Arch. Gen. Psychiatry, 2005, 62(2), 146-152.
81. Hariri, A.R.; Holmes, A. Genetics of emotional regulation: the role of the serotonin transporter in neural function. Trends Cogn. Sci., 2006, 10(4), 182-191.
82. Furmark, T.; Tillfors, M.; Garpenstrand, H.; Marteinsdottir, I.; Langstrom, B.; Oreland, L.; Fredrikson, M. Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social phobia. Neurosci. Lett., 2004, 362(3),189-192.
83. Van der Linden, G.; van Heerden, B.; Warwick, J.; Wessels, C.; van Kradenburg, J.; Zungu-Dirwayi, N.; Stein, D.J. Functional brain imaging and pharmacotherapy in social phobia: single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2000, 24(3), 419-438.
84. Jetty, P.V.; Charney, D.S.; Goddard, A.W. Neurobiology of generalized anxiety disorder. Psychiatr. Clin. North Am., 2001, 24(1), 75-97.
85. Hoehn-Saric, R.; Schlund, M.W.; Wong, S.H. Effects of citalopram on worry and brain activation in patients with generalized anxiety disorder. Psychiatry Res., 2004, 131(1), 11-21.
86. Simmons, A.N.; Arce, E.; Lovero, K.L.; Stein, M.B.; Paulus, M.P. Subchronic SSRI administration reduces insula response during affective anticipation in healthy volunteers. Int. J. Neuropsychopharmacol., 2009, 12(8), 1009-1020.
87. Del-Ben, C.M; Ferreira, C.A.; Alves-Neto, W.C.; Graeff, F.G. Serotonergic modulation of face-emotion recognition. Braz. J. Med. Biol. Res., 2008, 41(4), 263-269.
88. Harmer, C.J.; Shelley, N.C.; Cowen, P.J.; Goodwin, G.M. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am. J. Psychiatry, 2004, 161(7), 1256-1263.
89. Harmer, C.J.; Mackay, C.E.; Reid, C.B.; Cowen, P.J.; Goodwin, G.M. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol. Psychiatry, 2006, 59(9), 816-820.
90. Johnson, P.L.; Truitt, W.A.; Fitz, S.D.; Lowry, C.A., Shekhar, A. Neural pathways underlying lactate-induced panic. Neuropsychopharmacology, 2008, 33(9), 2093-2107.